Medical Aesthetics - Jiangsu Chuangjian Medical Technology Co., Ltd. received approval for its cross-linked recombinant collagen implant, marking a significant development in the medical aesthetics market [2][17] - The product is designed for facial dermal tissue filling to correct moderate to severe dynamic wrinkles, making it the fifth recombinant collagen implant approved in China and the first cross-linked version [17] - The recombinant collagen industry is shifting from "single type" to "diverse structure," with companies accelerating competition towards full-scenario applications [18] Cosmetics - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, officially listed on the Hong Kong Stock Exchange, becoming the first high-end domestic skincare brand to go public [3][19] - The company has established a comprehensive supply chain system and a unique OMO (Online-Merge-Offline) channel model, which integrates online and offline sales to enhance customer engagement and drive growth [23][35] - Lin Qingxuan's flagship product, the camellia oil essence, has achieved a leading repurchase rate of 33.5% in the industry, indicating strong customer loyalty [27][46] Investment Recommendations - The company recommends focusing on differentiated upstream medical aesthetics product manufacturers and chain medical institutions, highlighting the potential of Meili Tianyuan Medical Health [4][48] - In the cosmetics sector, the emphasis is on domestic brands that innovate in emotional value and safe ingredients, with key recommendations including Lin Qingxuan and other brands that leverage both online and offline channels [4][47] Market Performance - In December, the beauty and personal care index fell by 1.70%, underperforming the broader market, while the medical aesthetics sector saw notable gains from companies like Meili Tianyuan Medical Health and Jinbo Biological [5][10] - For the full year of 2025, the medical aesthetics sector showed mixed performance, with companies like Sihuan Pharmaceutical and Yonghe Medical leading in growth [10] Financial Highlights - Lin Qingxuan reported a total revenue of 1.05 billion yuan in the first half of 2025, reflecting a year-on-year growth of 98.3%, primarily driven by its camellia oil essence [23][41] - The company's gross margin remains high at 82.4%, with specific product categories like essence oil achieving even higher margins [23][41]

Group 1 - The report highlights that the service industry is increasingly merging with technology, leading to the emergence of top-tier listed companies in sectors such as fintech, logistics, enterprise services, and healthcare [2][10] - Countries are exploring unique paths to develop their service industries, with examples including the U.S. focusing on fintech innovation, Germany emphasizing industrial design, and Singapore building digital infrastructure [2][10] - China's national strategy aims to enhance service industry capacity and quality through targeted policies, including the removal of entry barriers in key sectors like telecommunications and healthcare [2][39] Group 2 - The report identifies three main investment directions in the service industry: productive services, lifestyle services, and emerging services [2][45] - Productive services are seen as a core engine, with sectors like testing, industrial software, and financial services highlighted for their growth potential [2][3][45] - Lifestyle services are focused on improving living standards and consumption upgrades, with high growth observed in areas such as gaming, aviation, and tourism [3][45] Group 3 - Emerging services are positioned as key to cultivating new productive forces, with rapid developments in AI and the integration of healthcare and pharmaceutical services [4][45] - The report emphasizes the importance of cross-border e-commerce as a new growth driver for foreign trade, leveraging China's supply chain advantages [4][45] - Specific companies such as Cintas and CVS Health are cited as examples of successful service firms in the U.S., showcasing effective business models and market strategies [1][15][18]

Investment Rating - The industry investment rating is "Positive" (首次) [1] Core Insights - The beauty and personal care industry is experiencing a mixed performance, with the beauty care index declining by 1.70% in December 2025, ranking 24th among all primary industries [15] - The medical beauty sector is seeing innovation with the approval of new products, such as the cross-linked recombinant collagen implant by Jiangsu Chuangjian Medical Technology Co., which is expected to inject new momentum into the market [7][34] - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone for domestic high-end skincare brands [8][39] Summary by Sections Market Review - In December, the beauty care index reported a decline of 1.70%, underperforming the broader market, which saw the Shanghai Composite Index increase by 2.06% [15] - For the entire year of 2025, the beauty care index showed a cumulative increase of 0.39%, again lagging behind the Shanghai Composite Index's 18.41% growth [15] Medical Beauty - Jiangsu Chuangjian Medical's cross-linked recombinant collagen implant has been approved, making it the fifth such product in China and the first cross-linked version [34] - The industry is shifting from single product competition to a full-chain layout, with companies like Jinjian Biological and Junzi Biological also making significant advancements in the recombinant collagen space [34][36] Cosmetics - Lin Qingxuan has established itself as a leader in the high-end domestic skincare market, achieving the highest retail sales among domestic brands in 2024 [39] - The company has built a comprehensive supply chain and employs an OMO (Online-Merge-Offline) model to enhance customer engagement and sales [39][49] - Lin Qingxuan's core product, the camellia oil essence, has a high repurchase rate of 33.5%, indicating strong customer loyalty [51] Investment Recommendations - The report recommends focusing on differentiated upstream medical beauty product manufacturers and chain medical beauty institutions, highlighting companies like Meili Tianyuan Medical Health and Aimeike [9][53] - In cosmetics, the report suggests investing in brands that innovate in emotional value and safe ingredients, with a focus on domestic brands like Maogeping and Lin Qingxuan [54]

Core Viewpoint - The approval of the injectable type A botulinum toxin product from Huons BioPharma marks a significant milestone for the company, enhancing its strategic positioning in the competitive Chinese medical aesthetics market, which is characterized by a growing number of similar products [2][3]. Group 1: Company Developments - The company has been seeking new growth avenues beyond its core hyaluronic acid business, with the injectable botulinum toxin being one of its earliest product initiatives [2]. - The company signed an exclusive agency agreement with Huons Global in September 2018, which was later deepened by acquiring a 25.4% stake in Huons BP in June 2021 [3]. - The recent approval is expected to enrich the company's product matrix and allow for comprehensive solutions for clients, aligning with market expectations for product pricing and positioning [3][6]. Group 2: Market Context - The Chinese medical aesthetics market has seen significant changes over the past seven years, with the number of approved botulinum toxin products increasing to seven, including the newly approved product from Huons BP [7]. - The market was previously dominated by two brands, Botox and Hengli, which held a combined market share of 100% until recent years [7]. - The current market dynamics indicate that while new entrants may face challenges due to intense competition and price pressures, there is still potential for growth, particularly in the mid-to-high-end market segment [9]. Group 3: Stock Market Reaction - Following the announcement of the product approval, the company's stock price rose by 2.69%, reflecting positive market sentiment [5].

证券日报网讯 1月9日，爱美客（300896）在互动平台回答投资者提问时表示，医美行业正从高速增长 向高质量发展转型，各项监管新政策的出台有利于加速行业洗牌与合规化进程。企业竞争不只是产品价 格的竞争，还包括品牌、技术与服务、行业整合能力等因素。公司将通过不断提升核心竞争力，优化客 户服务，推进公司业务的稳定可持续发展。 ...

（文章来源：证券日报） 证券日报网讯 1月9日，爱美客在互动平台回答投资者提问时表示，公司注射用A型肉毒毒素在韩国市场 已积累多年临床应用数据，其临床安全与稳定性得到了市场的验证，该产品通过与公司现有产品的组 合，能为客户提供更全面的综合解决方案，有利于增强公司的核心竞争力。 ...

Investment Rating - The report gives a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26][32]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 3.61% from December 26, 2025, to January 8, 2026, exceeding the CSI 300 index by approximately 1.56 percentage points [12]. - Most sub-sectors within the industry recorded positive returns during the same period, with the hospital and medical R&D outsourcing sectors leading with increases of 10.62% and 7.39%, respectively [13]. - Approximately 82% of stocks in the industry achieved positive returns, with notable performers including Xiangyu Medical, which saw a weekly increase of 57.50% [14][17]. - The overall industry valuation has risen, with the SW pharmaceutical and biotechnology index's PE (TTM) at approximately 52.75 times, which is 3.78 times higher than the CSI 300 index [18][26]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 3.61% from December 26, 2025, to January 8, 2026 [12]. - Most sub-sectors recorded positive returns, particularly hospitals and medical R&D outsourcing, which increased by 10.62% and 7.39%, respectively [13]. - About 82% of stocks in the industry had positive returns, with significant gains from several companies [14]. 2. Industry News - The report highlights the acceleration of volume-based procurement in 2026, with various local and national initiatives underway to streamline drug procurement processes [24]. - A new batch of encouraged generic drugs has been announced, focusing on optimizing the drug supply system and enhancing the availability of essential medications [23]. 3. Company Announcements - Jiangsu Yahui Pharmaceutical announced the completion of the first patient enrollment in a Phase I clinical trial for its drug APL-2401, targeting advanced solid tumors [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, particularly following announcements from Neuralink regarding large-scale production plans [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28][29].

（原标题：今年起整容要交税了！超5成医美相关企业成立近三年，集中三线城市） 企查查数据显示，从经营时间来看，超五成医美相关企业在近三年成立，其中，成立年限在1-3年的相 关企业最多，占比38.27%。其次，成立年限在1年内的相关企业占比20.84%。 据一财报道，《中华人民共和国增值税法》和《中华人民共和国增值税法实施条例》自2026年1月1日起 施行。其中，增值税法在税收优惠一章中，明确了"医疗机构提供的医疗服务"免征增值税。值得注意的 是，营利性美容医疗机构不在增值税法实施条例定义的"医疗机构"范畴内。此外，相关人士介绍，今年 之前增值税相关规定中，并没有将营利性美容医疗机构排除在上述免税政策范围外。而从今年开始，只 要是营利性美容医疗机构，将不再享受上述免征增值税优惠政策。 企查查数据显示，截至1月8日，国内现存医美相关企业18.69万家。随着颜值主义的盛行及"悦己消 费"的风靡，近十年医美迎来快速发展时期，行业规模不断扩大，从相关企业年末存量分布来看，2022 年末医美相关企业存量首次突破十万家，达10.21万家。2025年末全国医美相关企业存量达18.61万家。 从经营时间来看，超5成医美相关企业在 ...

Product Launch and Development - In November and December 2025, the company launched a total of 18 new products, with 9 in medical devices and 9 in cosmetics [1] - The company has a clinical-stage medical device, "Recombinant Type III Humanized Collagen Dressing," and is preparing for clinical trials for other collagen-based products [2] Financial Performance and Sales Strategy - The company is currently finalizing its financial results for 2025, with sales data impacted by adjustments in offline sales channels [2] - The transition from traditional distribution to value-driven sales models is expected to improve long-term health in offline business [2] Margin and Cost Management - The company is experiencing pressure on profit margins due to high online sales costs and adjustments in offline sales channels [4] - The fluctuation in gross margin is attributed to increased competition and changes in product mix, with plans for optimization in production, pricing, and supply chain management [2] Channel Optimization and Inventory Management - The company is optimizing its offline channels, focusing on better inventory management and strategic partnerships with service-oriented distributors [4] - Current adjustments in offline channels are expected to have manageable impacts on performance, laying the groundwork for future growth [4] Future Plans and Incentives - The company expresses a strong intention to implement an equity incentive plan as the management team evolves [4]

Core Insights - Hangzhou has achieved significant results in the comprehensive governance of prepaid consumption, launching a social co-governance action for integrity in business and a market-oriented reform plan for promotion across the province [1] Group 1: Government Initiatives - Hangzhou is the first city in China to define administrative departments involved in prepaid consumption management by industry supervision, comprehensive regulation, and law enforcement [1] - The city has strengthened inter-departmental collaboration and improved the risk warning and disposal mechanism, incorporating prepaid consumption into industry credit governance [1] - By the end of November 2025, the city received and handled 19,000 complaints related to closed prepaid consumption businesses, a year-on-year decrease of 19.23%, with the largest declines in education and training (59.37%) and sports fitness (29.36%) [1] Group 2: Market Developments - Hangzhou has actively developed a new model of platform economy, supporting the launch of market-oriented products such as Ant Group's "Anxin Pay" and Meituan's "Anxin Study" [1] - By the end of November 2025, the city had secured 562 million yuan in funds for consumer safety through these platforms [1] - The Gongshu District has implemented market-oriented reforms in prepaid consumption, covering 6,256 merchants across 21 sub-sectors, ensuring the safety of 110 million yuan in funds [2] Group 3: New Policies and Incentives - Three new policy measures were announced, allowing prepaid payments through compliant third-party platforms to be exempt from card issuance registration and to exceed the 5,000 yuan limit [2] - Businesses participating in the new prepaid consumption safety management model can receive up to 200,000 yuan in support for high-quality development from the city [2] - The first batch of 99 one-star stores in the beauty and hairdressing industry was announced, along with 13 stores in the "credit + sports consumption" application scenarios [2] Group 4: Collaborative Efforts - Ant Group announced the upgrade of "Anxin Pay 2.0," while Meituan launched the "Anxin Study Credit List" [3] - Representatives from government, consumers, and industry associations initiated a provincial promotion map for market-oriented reforms, marking the transition of the "Hangzhou experience" from pilot exploration to provincial deepening [3]